Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-17
2007-04-17
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S557000, C549S419000, C549S420000, C562S405000
Reexamination Certificate
active
10363988
ABSTRACT:
The invention relates to a multimeric compound or a pharmaceutically acceptable salt or derivative thereof which comprises three or more neuraminidase-binding groups attached to a spacer or linking group, in which the neuraminidase-binding group is a compound which binds to the active site of influenza virus neuraminidase, but is not cleaved by the neuraminidase. The invention also relates to processes for the preparation of the multimeric compound defined above, pharmaceutical compositions containing them or methods for the treatment and/or prophylaxis of a viral infection involving them.
REFERENCES:
patent: 6022888 (2000-02-01), Morishige et al.
patent: 0 823 428 (1998-02-01), None
patent: WO 91/16320 (1991-10-01), None
patent: WO 95/18800 (1995-07-01), None
patent: WO 95/20583 (1995-08-01), None
patent: WO 95/34595 (1995-12-01), None
patent: WO 95/34595 (1995-12-01), None
patent: WO 96/26933 (1996-09-01), None
patent: WO 97/06157 (1997-02-01), None
patent: WO 97/32214 (1997-09-01), None
patent: WO 97/47194 (1997-12-01), None
patent: WO 98/03572 (1998-01-01), None
patent: WO 98/03572 (1998-01-01), None
patent: WO 98/06712 (1998-02-01), None
patent: WO 98/21243 (1998-05-01), None
patent: WO 98/21243 (1998-05-01), None
patent: WO 99/33781 (1999-07-01), None
patent: WO 00/55149 (2000-09-01), None
patent: WO 00/55149 (2000-09-01), None
Mathai Mammen et al., “Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors”, Angew. Chem. Int. Ed. 1998, 37, 2754-2794.
George B. Sigal et al., “Polyacrylamides Bearing Pendant α-Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus: The Strong Inhibition Reflects Enhanced Binding through Cooperative Polyvalent Interactions”, Journal of the American Chemical Society, vol. 118, No. 16, Apr. 24, 1996, pp. 3789-3800.
Mathai Mammen et al., “Effective Inhibitors of Hemagglutination by Influenza Virus Synthesized from Polymers Having Active Ester Groups, Insight into Mechanism of Inhibition”, J. Med. Chem. 1995, 38, 4179-4190.
Jon D. Reuter et al., “Inhibition of Viral Adhesion and Infection by Sialic-Acid-Conjugated Dendritic Polymers”, Bioconjugate Chem. 1999, 10, 271-278.
Frederick G. Hayden et al., “Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections”, The New England Journal of Medicine, Sep. 25, 1997, pp. 874-880.
P. Meindl et al., “Inhibition of Neuraminidase Activity by Derivatives of 2-Deoxy-2, 3-dehydro-N-acetylneuraminic Acid”, Virology 58, 457-463 (1974).
Dowle Michael Dennis
Jin Betty
Macdonald Simon John Fawcett
Mason Andrew McMurtrie
McConnell Darryl
Foley & Lardner LLP
Shameem Golam M. M.
Shiao Robert
LandOfFree
Multivalent neuraminidase inhibitor conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent neuraminidase inhibitor conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent neuraminidase inhibitor conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807433